Edition:
United Kingdom

TRACON Pharmaceuticals Inc (TCON.OQ)

TCON.OQ on NASDAQ Stock Exchange Global Market

3.00USD
15 Dec 2017
Change (% chg)

$0.05 (+1.69%)
Prev Close
$2.95
Open
$2.95
Day's High
$3.00
Day's Low
$2.95
Volume
300
Avg. Vol
22,235
52-wk High
$6.20
52-wk Low
$2.00

Chart for

About

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company's research focuses on antibodies that bind to the endoglin receptor, which is... (more)

Overall

Beta: --
Market Cap(Mil.): $61.63
Shares Outstanding(Mil.): 16.66
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Tracon Pharmaceuticals announces positive results from phase 1 trial of TRC102, Fludara

* Tracon Pharmaceuticals announces positive results from phase 1 trial of trc102 and fludara® in patients with advanced hematologic malignancy published in oncotarget

13 Nov 2017

BRIEF-Tracon Pharma reports third quarter financial results

* Tracon Pharmaceuticals reports third quarter financial results and provides corporate update

07 Nov 2017

BRIEF-683 Capital Management reports 5.4 pct passive stake in Tracon Pharmaceuticals

* 683 Capital Management Llc reports 5.4% passive stake in Tracon Pharmaceuticals Inc as of Sept 18, 2017 - SEC filing‍​ Source text: [http://bit.ly/2yb8Zbn] Further company coverage:

28 Sep 2017

BRIEF-Tracon Pharmaceuticals announces completion of enrollment in randomized phase 2B traxar study of TRC105 and Inlyta in renal cell carcinoma

* Tracon Pharmaceuticals announces completion of enrollment in randomized phase 2B Traxar study of TRC105 and Inlyta in renal cell carcinoma

07 Sep 2017

BRIEF-Tracon Pharmaceuticals files for offering of up to $14.33 mln of co's common stock‍​

* Files for offering of up to $14.33 million of co's common stock‍​ - SEC filing Source text for Eikon: Further company coverage:

05 Sep 2017

BRIEF-Tracon Pharmaceuticals announces positive results for phase 1/2 trial of TRC105 and Nexavar

* Tracon Pharmaceuticals announces positive results from National Cancer Institute Phase 1/2 trial of TRC105 and Nexavar in Hepatocellular cancer published in Clinical Cancer Research

16 Aug 2017

BRIEF-Tracon Pharmaceuticals qtrly net loss per share $0.40

* Tracon Pharmaceuticals reports second quarter financial results and provides corporate update

08 Aug 2017

BRIEF-Santen and Tracon announce initiation of a phase 2a study of drug for the treatment of wet age-related macular degeneration

* Santen and Tracon announce initiation of a phase 2a study of DE-122 for the treatment of wet age-related macular degeneration

26 Jul 2017

Earnings vs. Estimates